Kelly Financial Services LLC Immuno Gen, Inc. Transaction History

Kelly Financial Services LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 17, 2024	SELL	$0.0 - $31.23 $0 - $3,123	-100 Closed	0 $0
Q3 2021 Jul 17, 2024	SELL	$5.02 - $6.59 $2,806 - $3,683	-559 Reduced 84.83%	100 $567,000
Q2 2021 Jul 17, 2024	BUY	$5.79 - $8.6 $3,236 - $4,807	559 Added 559.0%	659 $100,000
Q1 2020 Jul 17, 2024	SELL	$2.12 - $6.8 $466 - $1,496	-220 Reduced 68.75%	100 $341,000
Q4 2019 Jul 17, 2024	BUY	$2.25 - $5.8 $495 - $1,276	220 Added 220.0%	320 $1.63 Million
Q1 2019 Jul 17, 2024	BUY	$2.41 - $5.91 $241 - $591	100 New	100 $271,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Kelly Financial Services LLC, based on Form 13F filings with the SEC.

Stay updated on Kelly Financial Services LLC with notifications on news.